Baptist Health Lexington

Amy M Schell

Principal Investigator

Leah Shore (LEX)

Want to join the trial?

Choose a location to contact our Clinical Trial Coordinator and to discuss potential opportunities.

Email Coordinator


TOL2506A: A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor Positive

This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The study will also aim to assess administration of TOL2506 in men with HR+ breast cancer. Study duration, for individual subjects, will be up to 57 weeks, including a Screening Period of up to 9 weeks, a Treatment Period of 48 weeks, and an End of Study Visit (Visit 8, Week 48). Eligible subjects will enter into the Treatment Period in 1 of 2 groups: those who will receive tamoxifen concurrently with TOL2506 or those who will initiate therapy with an AI (letrozole, anastrozole, or exemestane) beginning 6 weeks after the first administration of TOL2506, upon confirmation that estradiol (E2) levels of < 20 pg/mL have been achieved. After Week 12, subjects will be allowed to switch from receiving an AI to receiving tamoxifen or from tamoxifen to AI at the discretion of the Investigator. However, a switch is not permitted 28 days prior to a dosing visit. At the end of the Treatment Period, subjects will be eligible for compassionate use of TOL2506 (expanded access) until TOL2506 receives marketing approval and is commercially available.

Learn more at
Eligibility Criteria


  • Able to understand the investigational nature of this study and provide written informed consent prior to the participation in the trial
  • Age 18 to 55, inclusive
  • Diagnosis of Stage I, II, or III HR+, HER2-negative breast cancer (ER>1% and/or, PR>1%, HER2-negative per ASCO CAP guidelines)
  • Is a candidate for endocrine therapy + ovarian suppression
  • Is premenopausal at the time of study entry.
  • E2 > 30 pg/mL
  • Follicle stimulating hormone (FSH) < 40 IU/L
  • Last menstrual period within the 3 months prior to first dose of TOL2506


  • Body mass index (BMI) < 18.00 kg/m2 or > 35.00 kg/m2
  • Breastfeeding
  • Life expectancy < 12 months
  • Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3
  • Unacceptable hepatic function as determined by any of the following:
    • Alanine aminotransferase (ALT) ≥ 2X upper limit of normal (ULN)
    • Aspartate aminotransferase (AST) ≥ 2X ULN
    • Bilirubin ≥ 2X ULN
    • Alkaline phosphatase ≥ 2X ULN
    • Severe hepatic impairment (Child-Pugh Class C)
    • Unacceptable renal function as determined by any of the following:
      • Creatinine ≥ 3X ULN
      • Creatinine clearance ≤ 30 mL/minute
      • Creatinine clearance ≤ 60 mL/minute in subjects with bone density 1.5 standard deviations below the young adult normal mean
  • History of significantly abnormal ECG or screening 12-lead ECG demonstrating any of the following:
    • HR > 100 BPM
    • QRS > 120 msec
    • QTc > 450 msec
    • PR > 220 msec
    • Prior (within 28 days prior to Day 0) and/or concomitant use of medications known to prolong the QT/QTc interval
    • Prior use of tamoxifen, other SERMs (eg, raloxifene) or antagonists (eg, fulvestrant), aromatase inhibitor, mammalian target of rapamycin (mTOR) inhibitors, or hormone replacement therapy within 3 months before breast cancer diagnosis
    • Prior neoadjuvant or adjuvant endocrine therapy since diagnosis of breast cancer
    • History of treatment for osteopenia/osteoporosis
    • Prior or current use of drugs or supplements known to increase bone mineral density (ie, bisphosphonates, denosumab, teriparatide, abaloparatide, romosozumab, calcitonin, fluoride, strontium)
    • Low trauma fracture(s) occurring within 12 months prior to Screening (defined as a fracture that results from a fall from a standing height or less, excluding fingers, toes, face and skull)
    • Conditions that preclude bone mineral density measurement (lumbar spine/bilateral hip surgery with hardware in place, abdominal clips, umbilical ring [not willing to remove] or weight that exceeds the DEXA machine limitation)
    • Any other medical condition or serious illness, presence of a second malignancy under current treatment or follow-up, or the presence of clinically significant findings on the physical exam, laboratory testing, medical history (including conditions that may be associated with low bone mass), that in the opinion of the Investigator may interfere with trial conduct, subject safety, or interpretation of study results
    • Already receiving and/or previously received GnRH analogs within 1 year before breast cancer diagnosis
    • Psychiatric, addictive, or other disorders that would preclude study compliance
  • Use of medications that may impact subject safety and/or affect the PK of the drug and hormonal assessments including but not limited to:
    • Oral or transdermal hormonal therapy within 30 days prior to Screening
    • Estrogen, progesterone, or androgens within 30 days prior to Screening
    • Hormonal contraceptives within 30 days prior to Screening
    • Medications known to result in clinically important decreases in bone mass taken within 6 months prior to Screening
    • Known hypersensitivity, idiosyncratic, or allergic reactions to GnRH, GnRH agonist/analogs or to any of the components of the IP
    • Sexually active with a male partner and not willing to use non-hormonal contraceptive methods throughout the study
    • Is of childbearing potential with a positive serum pregnancy test at Screening or urine pregnancy test at Day 0
    • Exposure to any investigational agent within 30 days prior to the first dose of TOL2506
    • See contact information to obtain inclusion/exclusion criteria for males